

SIR ANNUAL MEMBERS' BUSINESS MEETING TUESDAY, MARCH 26, 2024 7–8 a.m. MT Salt Lake City, Utah

Welcome and Introductions

- Recap of standing rules Robert Lookstein, MD, FSIR, SIR Secretary
 Dr. Lookstein reviewed the revised Robert's rules that govern the members' business meeting.
- Welcome and call to order Alda Tam, MD, MBA, FSIR, SIR President
 Meeting came to order at 7:03 am MT
 Dr. Tam welcomed attendees to the annual Members' Business Meeting at Salt Lake City.
- Recognition of SIR Past President William J. Casarella, MD, FSIR, in honor of his passing Dr. Tam asked the gathering to hold a moment of silence for Dr. Casarella
- Vote to approve 2023 Annual Members' Business Meeting Minutes
 Dr. Lookstein called for a vote to approve the 2023 Annual Members' Business Meeting Minutes.
 There were no questions or discussion.

The minutes of the 2023 Annual Members' Business Meeting were approved via voice vote.

Society Update

SIR President's report – Alda Tam, MD, MBA, FSIR
 Dr. Tam reflected on 2023 as a year of growth and engagement for SIR. Membership is now at 8,500 members, with an active group of trainee members. There are 7 sections and 8 Clinical Specialty Councils working to move IR initiatives forward. Dr. Tam thanked the over 800 member volunteers in the sections and on committees and councils serving the IR membership.

Dr. Tam reviewed the educational content held in 2023 and coming in the future. The SIR EDGE meeting for advanced practitioners seeking to obtain deeper clinical knowledge on Y-90, peripheral vascular disease, MSK/pain management and portal hypertension will have its first meeting this October.

The Government Affairs Committee and team introduced 5 new category 1 codes. 2023 marked the return of SIR's in-person events on Capitol Hill. SIR hosted 3 briefings for congressional offices covering PAE and PVD. We also hosted our first in-person fly-in since 2019 where IRs from around the country met with 35 congressional representative's offices.

Dr. Tam presented on the SIR Business Institute, now in its 2nd year, which has received good feedback. The program has issued 16 letters to CMS and commercial payers and created 5 new carrier advocacy letters. There have been 352 business institute attendees in person and online.

CAP continues to do well, and we also remain engaged with the corporate community, and we thank our Corporate Ambassador Program members for their support.

2024-2025

Introduction of 2024 SIR Board of Directors and SIR Foundation Board of Directors;
 acknowledgement of outgoing leaders – Alda Tam, MD, MBA, FSIR, SIR President

Dr. Tam introduced the officers of the 2024 SIR Board of Directors: Robert J. Lewandowski, MD, FSIR, President Robert A. Lookstein, MD, FSIR, President-elect Saher S. Sabri, MD, FSIR, Secretary Raymond W. Liu, MD, FSIR, Treasurer

Andrew J. Gunn, MD, FSIR, Renal and GU Council Vice Chair

And the new members of the Board of Directors and vice chairs of the Clinical Specialty Councils: Kelvin Hong, MD, FSIR, Director-at-large
Sun-Ho Ahn, MD, FSIR, Education Division Councilor
Paula Novelli, MD, FSIR, 2024-2030 Annual Program Committee
Joseph J. Gemmete, MD, FSIR, Neurointerventional Radiology Council Vice Chair
Gulraiz Chaudry, MD, FSIR, Pediatric IR Council Vice Chair

Dr. Tam thanked the outgoing members of leadership for their service to SIR: Parag J. Patel, MD, FSIR, Immediate Past President Akhilesh Sista, MD, FSIR, Director-at-Large Erik N.K. Cressman, MD, PhD, FSIR, Annual Scientific Meeting Division Councilor Kelvin Hong, MD, FSIR, Post Graduate Education Division Councilor Venu Vadlamudi, MD, FSIR, Neurointerventional Radiology Councilor Shellie Josephs, MD, FSIR, Pediatric IR Councilor Gordon McLennan, MD, FSIR, Renal and GU Councilor

• SIR Foundation Chair's report – Maureen P. Kohi, MD, FSIR

Dr. Kohi reviewed the foundation's invested funding, highlighting very diverse grant funding. She presented the grants distributed by clinical specialty.

Dr. Kohi remarked on the gift of research grants from Dr. John Lipman of \$500K to the SIR Foundation, in honor of James B. Spies, MD, FSIR, and Scott C. Goodwin, MD, MBA, FSIR, to focus on women's health interventions.

She reviewed the announcement earlier at the Annual Scientific Meeting of EMBOLIZE, noting for the first time in SIR Foundation history that the foundation is co-sponsoring a major trial. The trail is supported by the VIVA Foundation and corporate partner Penumbra. This trial came to fruition as a result of an RCP a few years ago.

Grants for Education of Medical Students (GEMS) and Summer Medical Internship Program (SMIP), two highly successful educational programs were highlighted. GEMS has had 53 students to date in their 3rd and 4th year all of these students matched in IR residency. SMIP has hosted 91 medical students to date, with 39 applicants for 2024.

Dr. Kohi announced the 2024–2025 Foundation Officers:

Maureen P. Kohi, MD, FSIR, Chair Clifford R. Weiss, MD, FSIR, Vice Chair Shellie C. Josephs, MD, FSIR, Secretary Raymond W. Liu, MD, FSIR, Treasurer

And the new members of the SIR Foundation Board of Directors: Robert A. Lookstein, MD, FSIR, SIR President-elect Shellie C. Josephs, MD, FSIR, Secretary Dania Daye, MD, PhD, Research Education and Outreach Division Chair

Dr. Kohi thanked the following members of leadership for their service to the SIR Foundation: Kathy Krol, MD, FSIR, SIR Foundation Immediate Past Chair Alda Tam, MD, FSIR, SIR President

SIR Treasurer's report – Raymond W. Liu, MD, FSIR

Dr. Liu began his presentation by noting the state of SIR finances is strong. He reviewed the total and nets assets, which have remained stable. The society's investments made money, which was drawn against to pay for programming.

The revenue versus expenses over past 6 years was presented, with the expenses driven by rising costs and investments into program. The 2023 expenses were driven by annual meeting and administration costs. SIR had a net loss of \$1.2MM for the 2023 fiscal year.

The SIR 2024 budget includes CAP, which is already at 85% of the forecasted revenue and continued growth is expected. Separately a capital expense budget with a major spend of \$985K on a website refresh. Expenses across the section budgets have increase due to other investments in new programs and activities.

In 2023 SIRPAC raised \$68K, remaining flat from last year. Dr. Liu stated membership can do better and encouraged attendees to donate and be involved via SIRConnect.

Dr. Liu moved on to the SIR Foundation finances. There are strong balance sheets the net assets are at \$3.4M, which are used to invest in the work of the foundation, supporting grants. Grant spending in 2023 was down and 46% of the expenses were on clinical research. The SIR Foundation ended the 2023 fiscal year with a loss of \$1.8MM. The 2024 budget continues grant spend down, decreasing expenses by \$329K.

There are two themes from the society and foundation budgets, the balance sheets are strong, but both organizations have had losses. The boards of directors take this very seriously, and a business development initiative has been started to focus on growth areas.

Vote to approve SIR membership 2024-2025 dues

Dr. Liu presented that for 2024 the SIR Finance Committee and both boards of directors support a proposal to increase dues at the member and associate levels. The suggested about averages to about 2.6%. This is below CPI and the inflation index. Due have not been increased in 3 years and those bodies feel this is a reasonable way to offset some losses and a fair ask of membership. The dues for an active member increase from \$950 to \$980 was recommended.

A brief discussion ensued.

The SIR membership 2024-2025 dues were approved via voice vote.

New Business: Proposed Bylaws Changes – Robert A. Lookstein, MD, FSIR, SIR Secretary

• Vote to approve the amendments to the SIR Bylaws

Dr. Lookstein reviewed the process of rules committee reviewing and endorsing the bylaws amendments. Minor grammatical organizational changes to bylaws, as well as governance changes, most notably the update of the standing committees section.

The amendments to the SIR Bylaws were approved via voice vote.

Adjournment

The business portion of the Annual Members' Business Meeting was closed at 7:54 a.m.

SIR Open Forum and Discussion

• Members at the podium: Let your voice be heard – Alda L. Tam, MD, MBA, FSIR, SIR President Dr. Tam opened the floor to discussion.

A discussion ensued.

